The short version of Cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-04. Anything still debated is marked as such rather than presented as settled.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Konrad Bloch and Feodor Lynen shared the Nobel Prize in Physiology or Medicine in 1964 for their discoveries concerning some of the mechanisms and methods of regulation of cholesterol and fatty acid metabolism.
=== Health care === In an interview with The Daily Record before becoming governor, Moore expressed support for the End-of-Life Options Act, which would allow terminally ill adults to request medical aid in dying. As of March 2025, bills to allow this procedure have stalled in the General Assembly because of a lack of support in the Maryland Senate. In January 2023, Moore proposed providing members of the Maryland National Guard with free health and dental care; legislators later amended the bill to cap monthly reimbursements at $60 a month, and it was signed into law by Moore in May 2023. Also in May 2023, he signed into law the Josh Siems Act, a bill that would require emergency rooms to include fentanyl testing in toxicology screens. In May 2024, Moore signed into law the Access to Care Act, which would allow Maryland residents to purchase individual private health care plans through the Maryland Health Benefit Exchange regardless of immigration status. During the 2025 legislative session, Moore proposed $200 million in cuts to the Developmental Disabilities Administration (DDA) to help offset a $3 billion budget deficit. Following pushback from disability advocates, state officials said that they had found a way to restore about 94% of the proposed budget cuts using unspent fund balance and federal assistance, and agreed to a three-month delay toward $73 million in DDA cuts that were set to go into effect in April 2025.
==== Increasing mandatory tests in California ==== Many rare diseases have not historically been tested for or testing that has been available has not been mandatory. One such disease is glutaric acidemia type I, a neurometabolic disease present in approximately 1 out of every 100,000 live births. A short-term California testing pilot project in 2003 and 2004 demonstrated the cost of forgoing rare disease testing on newborns. While both Zachary Wyvill and Zachary Black were both born with the same disease during the pilot program, Wyvill's birth hospital tested only for four state-mandated diseases while Black was born at a hospital participating in the pilot program. Wyvill's disease went undetected for over six months during which irreversible damage occurred but Black's disease was treated with diet and vitamin supplements. Both sets of parents became advocates for expanded neonatal testing and testified in favor of expanding tandem mass spectrometry (MS/MS) testing of newborns for rare diseases. By August, 2004, the California state budget law had passed requiring the use of tandem mass spectroscopy to test for more than 30 genetic illnesses and provided funding. California now mandates newborn screening for all infants and tests for 80 congenital and genetic disorders.
== History and programs == GAVI was created in 2000 as a successor to the Children's Vaccine Initiative, which was launched in 1990. In August 2014, Gavi changed its name from "GAVI Alliance" and rebranded itself with a new logo deliberately reminiscent of UN organization logos, but using green as a mark of difference. As mentioned above, Gavi plans its operations in terms of five-year stretegies to make it easier to negotiate longer-term deals. Gavi 6.0 (2026–2030) was approved by the Gavi board in June 2024. One of the goals is to build country-led, sustainable vaccination programs.
Beriate, freeze-dried human coagulation factor VIII concentrate Berinin P, freeze-dried human coagulation factor IX concentrate Factor X P Behring, a freeze-dried human coagulation factor IX and factor X concentrate Fibrogammin P, Cluvot and Corifact, freeze-dried human coagulation factor XIII concentrate Helixate FS and Helixate NexGen, freeze-dried recombinant coagulation factor VIII Humate-P and Haemate P, freeze-dried human coagulation factor VIII: C and von Willebrand factor concentrate Monoclate P, a freeze-dried monoclonal antibody purified human coagulation factor VIII concentrate Mononine, a freeze-dried human coagulation factor IX that has been purified using monoclonal antibodies Stimate, a synthetic desmopressin acetate nasal spray Octostim, a synthetic desmopressin acetate nasal spray Pulmonary:
Sources: en.wikipedia.org
Junior became the foundation chairman in 1917. Through the Laura Spelman Rockefeller Memorial (LSRM), established by Senior in 1918 and named after his wife, the Rockefeller fortune was for the first time directed to supporting research by social scientists. During its first few years of work, the LSRM awarded funds primarily to social workers, with its funding decisions guided primarily by Junior. In 1922, Beardsley Ruml was hired to direct the LSRM, and he most decisively shifted the focus of Rockefeller philanthropy into the social sciences, stimulating the founding of university research centers, and creating the Social Science Research Council. In January 1929, LSRM funds were folded into the Rockefeller Foundation, in a major reorganization. The Rockefeller family helped lead the foundation in its early years, but later limited itself to one or two representatives, to maintain the foundation's independence and avoid charges of undue family influence. These representatives have included the former president John D. Rockefeller III, and then his son John D. Rockefeller, IV, who gave up the trusteeship in 1981. In 1989, David Rockefeller's daughter, Peggy Dulany, was appointed to the board for a five-year term. In October 2006, David Rockefeller Jr. joined the board of trustees, re-establishing the direct family link and becoming the sixth family member to serve on the board.
There are four types of minicore myopathy Classical type (75% cases) The usual presentation is in infancy or childhood with hypotonia or proximal weakness. This weakness tends to affect the shoulder girdle and the inner thigh. The other main features are
Neoplasms – Renal cell carcinoma, liver tumors, Von Hippel–Lindau disease, and endocrine abnormalities including pheochromocytoma and adrenal adenoma with Cushing's syndrome. Anabolic steroid use – people whose testosterone levels are high, including athletes who abuse steroids, people on testosterone replacement for hypogonadism or transgender hormone replacement therapy. Blood doping – Athletes who take erythropoietin-stimulating agents or receive blood transfusions to increase their red blood cell mass. Post-transplant erythrocytosis – About 10–15% of patients after renal transplantation are found to have polycythemia at 24 months after transplantation, which can be associated with increased thrombotic (clotting) risk.
In December 2016, it was announced that Monster would replace Sprint Corporation as title sponsor of NASCAR's premier series. NASCAR's chief marketing officer cited Monster's "youthful and edgy" brands a driving force behind the deal. In April 2019, it was reported that NASCAR rejected Monster Energy's offer to extend its sponsorship through 2020 in favor of a new tiered sponsorship model. Monster is endorsed by NASCAR driver Ty Gibbs and sponsors his No. 54 Joe Gibbs Racing car, as well as his Toyota Racing teammate Riley Herbst and his No. 35 23XI Racing car through Terrible Herbst. They are also endorsed by Kurt Busch, who retired due to injuries after the 2022 season. They have also had sponsored Tyler Reddick, Robby Gordon, Ricky Carmichael, and the No. 54 Xfinity Series car of Joe Gibbs Racing/Kyle Busch Motorsports. Monster sponsored Formula 1 team Mercedes-AMG Petronas Motorsport between 2010 and 2023 and was endorsed by the team's drivers, George Russell and seven-time World Champion Lewis Hamilton. Hamilton also has a signature drink with the brand, "LH44". Monster Energy partnered with McLaren from the 2024 season onwards, including introducing a Lando Norris-inspired flavour featuring his helmet design on the can. The company will continue to sponsor Hamilton on a personal level. In September 2026, Monster became a sponsor of LN4 Fusion, a junior-level racing team co-founded by Norris.
Sources: en.wikipedia.org
== Biochemical details == Methionine (abbreviated as Met or M; encoded by the codon AUG) is an α-amino acid that is used in the biosynthesis of proteins. It contains a carboxyl group (which is in the deprotonated −COO− form under biological pH conditions), an amino group (which is in the protonated −NH+3 form under biological pH conditions) located in α-position with respect to the carboxyl group, and an S-methyl thioether side chain, classifying it as a nonpolar, aliphatic amino acid. In nuclear genes of eukaryotes and in Archaea, methionine is coded for by the start codon, meaning it indicates the start of the coding region and is the first amino acid produced in a nascent polypeptide during mRNA translation.
==== Side reactions ==== When methionine is followed by serine or threonine, side reactions can occur that destroy the methionine without peptide bond cleavage. Normally, once the iminolactone is formed (refer to figure), water and acid can react with the imine to cleave the peptide bond, forming a homoserine lactone and new C-terminal peptide. However, if the adjacent amino acid to methionine has a hydroxyl or sulfhydryl group, this group can react with the imine to form a homoserine without peptide bond cleavage. These two cases are shown in the figure.
Some historians assert that as many as 17 million people were sold into slavery on the coast of the Indian Ocean, the Middle East, and North Africa, and approximately 5 million African slaves were bought by Muslim slave traders and taken from Africa across the Red Sea, Indian Ocean, and Sahara Desert between 1500 and 1900. The captives were sold throughout the Middle East. This trade accelerated as superior ships led to more trade and greater demand for labour on plantations in the region. Eventually, tens of thousands of captives were being taken every year. The Indian Ocean slave trade was multi-directional and changed over time. To meet the demand for menial labour, Bantu slaves bought by east African slave traders from southeastern Africa were sold in cumulatively large numbers over the centuries to customers in Egypt, Arabia, the Persian Gulf, India, European colonies in the Far East, the Indian Ocean islands, Ethiopia, Sudan and Somalia. According to the Encyclopedia of African History, "It is estimated that by the 1890s the largest slave population of the world, about 2 million people, was concentrated in the territories of the Sokoto Caliphate. The use of slave labour was extensive, especially in agriculture." The Anti-Slavery Society estimated there were 2 million slaves in Ethiopia in the early 1930s out of an estimated population of 8 to 16 million. Slave labour in East Africa was drawn from the Zanj, Bantu peoples that lived along the East African coast.
== Children's future == In February 2020, a commission composed of the WHO, UNICEF, and The Lancet published a report of the investigation of the impact of two existential threats to children's health, the climate emergency and predatory commercial exploitation. It ranked 180 nations according to the steps taken by each to blunt these threats to the well-being of their children. Thailand ranked 64 of 180 nations (1=best). Eight other ASEAN nations were ranked: Singapore, 12; Malaysia, 44; Vietnam, 58; Philippines, 110; Cambodia, 114; Indonesia, 117; Myanmar, 120; Laos, 137.
Róza Ádány (born 11 December 1952, Berettyóújfalu) is a Hungarian physician, specialist in clinical laboratory diagnostics and in preventive medicine and public health, a university professor. She is the founding dean of the Faculty of Public Health at the University of Debrecen and an internationally recognized expert in public health education and research.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.